Crizotinib: from discovery to accelerated development to front-line treatment.
AffiliationChristie NHS Foundation Trust, Institute of Cancer Sciences, University of Manchester, Manchester
MetadataShow full item record
AbstractNon-small-cell lung cancer (NSCLC) is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options. The discovery of ALK gene rearrangements in a subset of NSCLC specimens and the identification and development of the first-in-class ALK inhibitor crizotinib provided a personalised treatment option for patients with advanced ALK-positive NSCLC. Crizotinib demonstrated rapid and durable responses in advanced ALK-positive NSCLC patients in phase I and II studies, leading to accelerated FDA approval. Subsequent evaluation in phase III studies showed that crizotinib improved progression-free survival compared with platinum-based doublet chemotherapy in previously untreated patients and compared with pemetrexed or docetaxel in previously treated patients. Crizotinib was shown to have an acceptable safety profile and also to improve quality of life and symptom scores. Overall, crizotinib has been shown to provide a valuable first- and second-line treatment option and is now the first-line standard of care for patients with advanced ALK-positive NSCLC.
CitationCrizotinib: from discovery to accelerated development to front-line treatment. 2016, 27(Suppl 3):iii35-iii41 Ann Oncol
JournalAnnals of Oncology
- Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.
- Authors: Frampton JE
- Issue date: 2013 Dec
- FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
- Authors: Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R
- Issue date: 2014 Oct
- Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
- Authors: Croegaert K, Kolesar JM
- Issue date: 2015 Sep 1
- Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
- Authors: Cameron L, Solomon B
- Issue date: 2015 Jul